News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This marks the fourth acquisition by Corona Remedies from multinational corporations
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Surpassing 1,000 Company Owned Company Operated stores
mRNA-1010 demonstrated superior relative vaccine efficacy
Subscribe To Our Newsletter & Stay Updated
